美国联合医疗（United Therapeutics）宣布，美国食品药品监督管理局（FDA）已批准其推进曲前列尼尔吸入粉雾剂（Treprostinil Smi）用于肺动脉高压合并慢性阻塞性肺疾病（Ph-Copd）的Summit临床试验。该试验获准继续开展。
美国联合医疗（United Therapeutics）宣布，美国食品药品监督管理局（FDA）已批准其推进曲前列尼尔吸入粉雾剂（Treprostinil Smi）用于肺动脉高压合并慢性阻塞性肺疾病（Ph-Copd）的Summit临床试验。该试验获准继续开展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.